Scott Byrd is Chief Executive Officer at Sudo Biosciences. He also serves as an Entrepreneur-in-Residence with Frazier Life Sciences.

Previously, he was Chief Executive Officer at Outpost Medicine from 2017 to 2021 and Chairman of the Board of Acacia Pharma Group plc from 2020 to 2022. From 2009 until its acquisition by Mallinckrodt Pharmaceuticals for $1.4 billion in 2014, he was Senior Vice President and Chief Commercial Officer of Cadence Pharmaceuticals. At Cadence, Scott built the company’s commercial and supply-chain infrastructure and led the launch of OFIRMEV, a market-leading non-opioid injectable analgesic. Earlier in his career, Scott served in a variety of roles of increasing responsibility at Eli Lilly and Company, including sales, marketing, development, manufacturing, and strategic planning.

Scott holds a B.S. in mechanical engineering from Bradley University and an M.B.A. from Harvard Business School.